Immunomodulative properties of conjugates composed of detoxified lipopolysaccharide and capsular polysaccharide of Vibrio cholerae O135 bound to BSA-protein carrier

Biologia

Volumn 65, Issue 5, 2010, Pages 768-775

  Korcová, Jana ^a   Machová, Eva ^a   Farkaš, Pavol ^a   Bystrický, Slavomír ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

antibodies; conjugates; lipopolysaccharide; Vibrio cholerae

Indexed keywords

MUS; VIBRIO CHOLERAE;

EID: 77955701518     PISSN: 00063088     EISSN: 13369563     Source Type: Journal    
DOI: 10.2478/s11756-010-0092-9     Document Type: Article

References (33)

1. Adams G. A. 1972. Lipopolysaccharides. Preparation from gramnegative bacteria. Methods Carbohydr. Chem. 6: 159-161.
2. Alexander J., Del Guercio M. F., Frame B., Maewal A., Sette A., Nahm M. H. & Newman M. J. 2004. Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE®. Vaccine 22: 2362-2367.
3. Amako K., Shimodori S., Imoto T., Miake S. & Umeda A. 2002. Effects of chitin and its soluble derivatives on survival of Vibrio cholerae O1 at low temperature. Appl. Environ. Microbiol. 53: 603-605.
4. Comstock L. E., Johnson J. A., Michalski J. M., Morris J. G. & Kaper J. B. 1996. Cloning and sequence of the region encoding a surface polysacharide of Vibrio cholerae O139 and characterization of the insertion site in the chromosome of Vibrio cholerae O1. Mol. Microbiol. 19: 815-826.
5. Dubois M., Gilles K. A., Hamilton, J. K., Rebers, P. A. & Smith, F. 1956. Colorimetric method for determination of sugar and related substances. Anal. Chem. 28: 350-358.
6. Farkaš P., Korcová J., Kronek J. & Bystrický S. 2010. Preparation of synthetic polyoxazoline based carrier and Vibrio cholerae O-specific polysaccharide conjugate vaccine. Eur. J. Med. Chem. 45: 795-799.
7. Fernandez-Miyakawa M. E., Brero M. L. & Mateo N. A. 2006. Cholera toxin modulates the systemic immune responses against Vibrio cholerae surface antigens after repeated inoculations. Microbiol. Immunol. 50: 607-619.
8. Glass R. I., Claeson M., Blake P. A., Waldman R. J. & Pierce N. F. 1991. Cholera in Africa: lessons on transmission and control for Latin America. Lancet. 338: 791-795.
9. Grandjean C., Boutonnier A., Dassy B., Mulard L. A. & Fournier, J. M. 2009. Investigation towards bivalent chemically defined glycoconjugate immunogens prepared from acid-detoxified lipopolysaccharide of Vibrio cholerae O1, serotype Inaba. Glycoconj. J. 26: 41-55.
10. Gupta R. K., Szu S. C., Filkenstein R. A. & Robbins J. B. 1992. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect. Immun. 60: 3201-3208.
11. Gupta R. K., Taylor D. N., Bryla D. A., Robbins J. B. & Szu S. C. 1998. Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysacharide-cholera toxin conjugates in adult volunteers. Infect. Immun. 66: 3095-3099.
12. Hisatsune K., Yamamoto F. & Kondo S. 1985. The acid hydrolysis, pp. 17-24. In Kuwahara S. & Pierce N. F. (eds) Advances in Research on Cholera and Related Diarrhoeas, KTK Scientific Publishers, Tokyo.
13. Holst O., Ulmer A. J., Brade H., Flad H. D. & Reitschel E. T. 1996. Biochemistry and cell biology of bacterial endotoxins. FEMS Immunol. Med. Microbiol. 16: 83-104.
14. Chatterjee S. N. & Chaudhury K. 2003. Lipopolysaccharides ofVibrio cholerae: I. Physical and chemical characterisation. Biochim. Biophys. Acta 1633: 65-79.
15. Chu C., Schneerson R., Robbins J. B. & Rastogi S. C. 1983. Further studies on immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect. Immun. 40: 245-256.
16. Janda J. M., Powers C., Bryant R. G. & Abbott S. L. 1988. Current perspective on the epidemiology and pathogenesis of clinically significant Vibrio spp. Clin. Microbiol. Rev. 1: 245-267.
17. Kaper J. B., Morris J. G. & Levine M. M. 1995. Cholera. Clin. Microbiol. Rev. 8: 48-86.
18. Kassis S., Hagmann J. & Fishman P. H. 1985. Mechanism of action of cholera toxin on intact cells. J. Biol. Chem. 257: 12148-12152.
19. Kerketta J. A., Paul A. C., Kirubakaran U. B., Jesudason M. U. & Moses P. D. 2002. Non-O1 Vibrio cholerae septicemia and meningitidis neonate. Indian J. Pediatr. 69: 909-910.
20. Kjellberg A., Weintraub A., Albert M. J. & Wildmam G. 1997. Structural analysis of the O-antigenic polysaccharide from Vibrio cholerae O10. Eur. J. Biochem. 249: 758-761.
21. Kondo S., Iguchi T. & Hisatsune K. 1988. A comparative study of the sugar composition of lipopolysaccharides isolated from Vibrio cholerae, 'Vibrio albensis' and Vibrio metschnikovii. J. Gen. Microbiol. 134: 1699-1705.
22. Kossaczka Z., Shiloach J., Johnson V., Taylor D. N, Finkelstein, A., Robbins J. B & Szu S. 2000. Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice. Infect. Immun. 68: 5037-5043.
23. Libjaková L., Bystrický S., Ližičárová I., Paulovičová E. & Machová E. 2007. Evaluation of different mannan polysaccharide usage in enzyme-linked immunosorbent assay for specific antibodies determination. J. Pharm. Biomed. Anal. 45: 521-525.
24. Machová E., Bystrický S., Gáliková A. & Kogan G. 2002. Preparation of a subcellular conjugate with the lipopolysaccharide from Vibrio cholerae 01 using β-D-glucan as matrix. Eur. J. Med. Chem. 37: 681-687.
25. Mukhopadhyay A., Basu K. A., Garg P., Bag P. K., Ghosh A., Bhattacharya S. K., Takeda Y. & Nair G. B. 1998. Molecular epidemiology of reemergent Vibrio cholerae O139 Bengal in India. J. Clin. Microbiol. 36: 2149-2152.
26. Paulovičová E., Machová E., Hoštacká A. & Bystrický, S. 2006. Immunological properties of complex conjugates based on Vibrio cholerae O1 Ogawa lipopolysaccharide antigen. Clin. Exp. Immunol. 144: 521-527.
27. Peeters C. C. A. M., Tenbergen-Meekes A. M. J., Poolman J. T., Zegers B. J. M. & Rijkers G. T. 1992. Immunogenicity of Streptococcus pneumoniae type 4 polysaccharide-protein conjugate vaccine is decreased by admixture of high doses of free saccharide. Vaccine 10: 833-840.
28. Poszgay V., Chu C., Pannel L., Wolfe J., Robbins J. B. & Schneerson R. 1999. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than to those of the O-specific polysaccharide from Shighela dysenteriae type 1. Proc. Natl. Acad. Sci. USA 96: 5194-5197.
29. Provenzano D., Kováč P. & Wade W. F. 2006. The ABCs (antibody, B cells and carbohydrate epitopes) of cholera immunity: considerations for an improved vaccine. Microbiol. Immunol. 50: 899-927.
30. Quadri F., Mohi G., Hossain J., Mannoor K., Begum Y. A., Mohi G., Salam M. A., Sack R. B. & Svennerholm A. M. 1995. Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1. Clin. Diagn. Lab. Immunol. 2: 685-688.
31. Robbins J. B., Schneerson R. & Szu S. C. 1995. Perspective: Hypothesis: Serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171: 1387-98.
32. Sedmak J. J. & Grossbergh S. E. 1977. A rapid, sensitive and versatile assay for protein using CBB G-250. Anal. Biochem. 79: 544-522.
33. Wasserman S. G., Losonsky F., Noriega C. O., Tacket E., Castaneda E. & Levine M. M. 1994. Kinetics of the vibriocidal antibody response to live oral cholera vaccines. Vaccine 11: 1000-1003.